Clinical work and research on diabetic
wound repair remain challenging globally. Although various conventional
wound dressings have been continuously developed, the efficacy is unsatisfactory. The effect of drug delivery is limited by the depth of penetration. The sustained release of biomolecules from biological
wound dressings is a promising treatment approach to wound healing. An assortment of cell-derived exosomes (exos) have been proved to be instrumental in tissue regeneration, and researchers are dedicated to developing biomolecules carriers with unique properties. Herein, we reported a
methacrylate gelatin (GelMA) microneedles (MNs) patch to achieve transdermal and controlled release of exos and
tazarotene. Our MNs patch comprising GelMA/PEGDA
hydrogel has distinctive biological features that maintain the biological activity of exos and drugs in vitro. Additionally, its unique physical structure prevents it from being tightly attached to the skin of the
wound, it promotes cell migration, angiogenesis by slowly releasing exos and
tazarotene in the deep layer of the skin. The full-thickness cutaneous
wound on a diabetic mouse model was carried out to demonstrate the
therapeutic effects of GelMA/PEGDA@T + exos MNs patch. As a result, our GelMA/PEGDA@T + exos MNs patch presents a potentially valuable method for repairing diabetic
wound in clinical applications.